What Others Have To Say About Ethikos

“While attending a Conference Board-sponsored ethics and compliance officer seminar last October, the question was asked: what do people in the ethics and compliance fields read? The overwhelming response was Ethikos....”
Dr. James Weber, Professor of Business Ethics and Management, Duquesne University, writing in the Winter 2007 issue of Ethics News.

“As an educator and researcher in business ethics, I need to stay abreast of developments and best company practices. Ethikos is an excellent source of information on both.”
Lynn Sharp Paine, John G. McLean Professor, Harvard Business School

About Ethikos

Founded in 1987, Ethikos is a bi-monthly publication that examines ethical issues in business.

From its inception, Ethikos has examined changes in the corporate ethics scene from the viewpoint of those involved: compliance officers, ethics officers, ombudspersons, practicing professionals in law, accounting, management, and government.

The publication reports on organizations' good and bad experiences in the business ethics and compliance area.

Sample articles include:

  • How Cisco Transmits Ethics To a 'Wired' Workforce
  • How Coca-Cola Structures Its Ethics Line
  • When Nexen Evacuated Its North Sea Platform
  • Taking the Floor at Novartis' Ethics Meetings
  • In Our Most Recent Issue

    • Plan International Teaches Ethics For A Greater Cause
    • Compliance and the Media
    • When Even A Kiss Can Cause FCPA Trouble
    • More Compliance Officers Report to the CEO
    • Do Wall Street’s Incentives Spur Wrongdoing?
    • More Misconduct During ‘Career Moments’

    Last Issue

    • At Boeing, ‘ethics advisor’ is an elevated position
    • How Parker Drilling Built an Effective Compliance Program in the Wake of an Investigation
    • What’s Next? Global Challenges of 2013
    • Expect More from SEC, Goelzer tells Ethics Summit
    • A case for ‘scenario-based’ ethics training.
    • Ethics simply ‘business as usual’— UK research report
    • America’s 100 Most Trustworthy Companies: Forbes
    • Pharma self-regulation a ‘ruse’ — study